TY - JOUR AU - Jabbour, Salma K. AU - Berman, Abigail T. AU - Simone II, Charles B. PY - 2017 TI - Integrating immunotherapy into chemoradiation regimens for medically inoperable locally advanced non-small cell lung cancer JF - Translational Lung Cancer Research; Vol 6, No 2 (April 27, 2017): Translational Lung Cancer Research (Combining Radiation Therapy and Immunotherapy for Thoracic Malignancies) 1 Y2 - 2017 KW - N2 - For patients with inoperable stage II–III non-small cell lung cancer (NSCLC), the backbone of curative intent therapy is concurrent chemoradiotherapy (CRT). As checkpoint inhibitors have shown clinical benefit in the setting of metastatic NSCLC, additional study is necessary to understand their role in patients receiving CRT. When integrating immunotherapy with radiotherapy (RT) for cure, clinicians will need to consider synergy, timing, doses, and safety among the combination of therapies. This article seeks to review data evaluating interactions, temporal sequencing, fractionation, and overlapping toxicity profiles of thoracic chemoradiation and immunotherapy. UR - https://tlcr.amegroups.org/article/view/13169